本季度信息
2026年上半年，启明医疗-B实现营收1.35亿元，同比下降27.6%。毛利约为0.94亿元，同比下降32.2%。经调整净利润0.08亿元，同比下滑72.7%。商业化利润率为6.1%，较上年同期下降10.1个百分点。经营活动现金流净额约为-1.61亿元，而上年同期为-1.12亿元。
业务分项
报告期内，TAVR业务收入从上年同期的约1.38亿元降至约0.80亿元，同比下降42.5%。TPVR业务保持增势，相关收入从上年同期约0.43亿元增至约0.56亿元，同比增长29.7%。其他业务收入则从上年同期559万元降至4万元，同比下降99.28%。
成本与费用方面，销售及分销开支为79.7百万元，同比下降20.7%；行政开支为51.7百万元，同比下降5.7%；研发投入约1.21亿元，较上年同期减少约6%。
高管解读 （本期无相关高管发言内容）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.